488 related articles for article (PubMed ID: 23142525)
1. Role of tau protein in neuronal damage in Alzheimer's disease and Down syndrome.
Cárdenas AM; Ardiles AO; Barraza N; Baéz-Matus X; Caviedes P
Arch Med Res; 2012 Nov; 43(8):645-54. PubMed ID: 23142525
[TBL] [Abstract][Full Text] [Related]
2. Normalizing the gene dosage of Dyrk1A in a mouse model of Down syndrome rescues several Alzheimer's disease phenotypes.
García-Cerro S; Rueda N; Vidal V; Lantigua S; Martínez-Cué C
Neurobiol Dis; 2017 Oct; 106():76-88. PubMed ID: 28647555
[TBL] [Abstract][Full Text] [Related]
3. Constitutive Dyrk1A is abnormally expressed in Alzheimer disease, Down syndrome, Pick disease, and related transgenic models.
Ferrer I; Barrachina M; Puig B; Martínez de Lagrán M; Martí E; Avila J; Dierssen M
Neurobiol Dis; 2005 Nov; 20(2):392-400. PubMed ID: 16242644
[TBL] [Abstract][Full Text] [Related]
4. The role of overexpressed DYRK1A protein in the early onset of neurofibrillary degeneration in Down syndrome.
Wegiel J; Dowjat K; Kaczmarski W; Kuchna I; Nowicki K; Frackowiak J; Mazur Kolecka B; Wegiel J; Silverman WP; Reisberg B; Deleon M; Wisniewski T; Gong CX; Liu F; Adayev T; Chen-Hwang MC; Hwang YW
Acta Neuropathol; 2008 Oct; 116(4):391-407. PubMed ID: 18696092
[TBL] [Abstract][Full Text] [Related]
5. N-butylidenephthalide attenuates Alzheimer's disease-like cytopathy in Down syndrome induced pluripotent stem cell-derived neurons.
Chang CY; Chen SM; Lu HE; Lai SM; Lai PS; Shen PW; Chen PY; Shen CI; Harn HJ; Lin SZ; Hwang SM; Su HL
Sci Rep; 2015 Mar; 5():8744. PubMed ID: 25735452
[TBL] [Abstract][Full Text] [Related]
6. HNE-modified proteins in Down syndrome: Involvement in development of Alzheimer disease neuropathology.
Barone E; Head E; Butterfield DA; Perluigi M
Free Radic Biol Med; 2017 Oct; 111():262-269. PubMed ID: 27838436
[TBL] [Abstract][Full Text] [Related]
7. Targeting increased levels of APP in Down syndrome: Posiphen-mediated reductions in APP and its products reverse endosomal phenotypes in the Ts65Dn mouse model.
Chen XQ; Salehi A; Pearn ML; Overk C; Nguyen PD; Kleschevnikov AM; Maccecchini M; Mobley WC
Alzheimers Dement; 2021 Feb; 17(2):271-292. PubMed ID: 32975365
[TBL] [Abstract][Full Text] [Related]
8. ets-2 promotes the activation of a mitochondrial death pathway in Down's syndrome neurons.
Helguera P; Pelsman A; Pigino G; Wolvetang E; Head E; Busciglio J
J Neurosci; 2005 Mar; 25(9):2295-303. PubMed ID: 15745955
[TBL] [Abstract][Full Text] [Related]
9. Neuropathological role of PI3K/Akt/mTOR axis in Down syndrome brain.
Perluigi M; Pupo G; Tramutola A; Cini C; Coccia R; Barone E; Head E; Butterfield DA; Di Domenico F
Biochim Biophys Acta; 2014 Jul; 1842(7):1144-53. PubMed ID: 24735980
[TBL] [Abstract][Full Text] [Related]
10. [Elucidating Pathogenic Mechanisms of Early-onset Alzheimer's Disease in Down Syndrome Patients].
Asai M; Kawakubo T; Mori R; Iwata N
Yakugaku Zasshi; 2017; 137(7):801-805. PubMed ID: 28674290
[TBL] [Abstract][Full Text] [Related]
11. DYRK1A antagonists rescue degeneration and behavioural deficits of in vivo models based on amyloid-β, Tau and DYRK1A neurotoxicity.
Zhu B; Parsons T; Foley C; Shaw Y; Dunckley T; Hulme C; Hodge JJL
Sci Rep; 2022 Sep; 12(1):15847. PubMed ID: 36151233
[TBL] [Abstract][Full Text] [Related]
12. A novel DYRK1A (dual specificity tyrosine phosphorylation-regulated kinase 1A) inhibitor for the treatment of Alzheimer's disease: effect on Tau and amyloid pathologies in vitro.
Coutadeur S; Benyamine H; Delalonde L; de Oliveira C; Leblond B; Foucourt A; Besson T; Casagrande AS; Taverne T; Girard A; Pando MP; Désiré L
J Neurochem; 2015 May; 133(3):440-51. PubMed ID: 25556849
[TBL] [Abstract][Full Text] [Related]
13. Exploring Alzheimer molecular pathology in Down's syndrome cerebrospinal fluid.
Portelius E; Soininen H; Andreasson U; Zetterberg H; Persson R; Karlsson G; Blennow K; Herukka SK; Mattsson N
Neurodegener Dis; 2014; 14(2):98-106. PubMed ID: 24992945
[TBL] [Abstract][Full Text] [Related]
14. Mitochondrial dysfunction and tau hyperphosphorylation in Ts1Cje, a mouse model for Down syndrome.
Shukkur EA; Shimohata A; Akagi T; Yu W; Yamaguchi M; Murayama M; Chui D; Takeuchi T; Amano K; Subramhanya KH; Hashikawa T; Sago H; Epstein CJ; Takashima A; Yamakawa K
Hum Mol Genet; 2006 Sep; 15(18):2752-62. PubMed ID: 16891409
[TBL] [Abstract][Full Text] [Related]
15. Untangle the mystery behind DS-associated AD - Is APP the main protagonist?
Elangovan A; Babu HWS; Iyer M; Gopalakrishnan AV; Vellingiri B
Ageing Res Rev; 2023 Jun; 87():101930. PubMed ID: 37031726
[TBL] [Abstract][Full Text] [Related]
16. Neprilysin Is Suppressed by Dual-Specificity Tyrosine-Phosphorylation Regulated Kinase 1A (DYRK1A) in Down-Syndrome-Derived Fibroblasts.
Kawakubo T; Mori R; Shirotani K; Iwata N; Asai M
Biol Pharm Bull; 2017; 40(3):327-333. PubMed ID: 28250274
[TBL] [Abstract][Full Text] [Related]
17. Impairment of proteostasis network in Down syndrome prior to the development of Alzheimer's disease neuropathology: redox proteomics analysis of human brain.
Di Domenico F; Coccia R; Cocciolo A; Murphy MP; Cenini G; Head E; Butterfield DA; Giorgi A; Schinina ME; Mancuso C; Cini C; Perluigi M
Biochim Biophys Acta; 2013 Aug; 1832(8):1249-59. PubMed ID: 23603808
[TBL] [Abstract][Full Text] [Related]
18. Neurons derived from sporadic Alzheimer's disease iPSCs reveal elevated TAU hyperphosphorylation, increased amyloid levels, and GSK3B activation.
Ochalek A; Mihalik B; Avci HX; Chandrasekaran A; Téglási A; Bock I; Giudice ML; Táncos Z; Molnár K; László L; Nielsen JE; Holst B; Freude K; Hyttel P; Kobolák J; Dinnyés A
Alzheimers Res Ther; 2017 Dec; 9(1):90. PubMed ID: 29191219
[TBL] [Abstract][Full Text] [Related]
19. Dual-specificity tyrosine(Y)-phosphorylation regulated kinase 1A-mediated phosphorylation of amyloid precursor protein: evidence for a functional link between Down syndrome and Alzheimer's disease.
Ryoo SR; Cho HJ; Lee HW; Jeong HK; Radnaabazar C; Kim YS; Kim MJ; Son MY; Seo H; Chung SH; Song WJ
J Neurochem; 2008 Mar; 104(5):1333-44. PubMed ID: 18005339
[TBL] [Abstract][Full Text] [Related]
20. In vitro modelling of Alzheimer's disease: degeneration and cell death induced by viral delivery of amyloid and tau.
Stoppelkamp S; Bell HS; Palacios-Filardo J; Shewan DA; Riedel G; Platt B
Exp Neurol; 2011 Jun; 229(2):226-37. PubMed ID: 21295028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
